(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer mini oral session included a presentation by Dr. Karim Fizazi discussing health-related quality of life, pain, and safety outcomes in the phase 3 VISION study. [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) delivers β-particle radiation to prostate-specific membrane antigen (PSMA) expressing cells and the surrounding microenvironment. In the phase III VISION study (NCT03511664), 177Lu-PSMA-617 + protocol-permitted standard of care prolonged radiographic progression-free survival (rPFS; HR 0.40, 99.2% CI 0.29-0.57), overall survival (OS; HR 0.62, 95% CI 0.52-0.74) and time to first symptomatic skeletal event (SSE, HR 0.50, 95% CI 0.40-0.62) versus standard of care (all p < 0.001) [1]. At the ESMO 2021 congress, Dr. Fizazi and colleagues presented health-related quality of life, pain assessments, and safety outcomes from VISION.